1. Home
  2. FLR vs BLCO Comparison

FLR vs BLCO Comparison

Compare FLR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluor Corporation

FLR

Fluor Corporation

HOLD

Current Price

$45.11

Market Cap

6.9B

Sector

Industrials

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.39

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLR
BLCO
Founded
1912
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Military/Government/Technical
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
FLR
BLCO
Price
$45.11
$17.39
Analyst Decision
Buy
Hold
Analyst Count
7
14
Target Price
$49.57
$17.31
AVG Volume (30 Days)
2.7M
413.8K
Earning Date
11-07-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
1235.20
N/A
EPS
20.04
N/A
Revenue
$15,587,000,000.00
$4,976,000,000.00
Revenue This Year
N/A
$8.08
Revenue Next Year
$5.34
$5.77
P/E Ratio
$2.24
N/A
Revenue Growth
N/A
6.23
52 Week Low
$29.20
$10.45
52 Week High
$57.50
$20.71

Technical Indicators

Market Signals
Indicator
FLR
BLCO
Relative Strength Index (RSI) 55.63 66.31
Support Level $42.39 $16.39
Resistance Level $46.00 $17.35
Average True Range (ATR) 1.49 0.48
MACD 0.35 0.08
Stochastic Oscillator 85.85 88.63

Price Performance

Historical Comparison
FLR
BLCO

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: